Off-label prescription of quetiapine in psychiatric disorders

References

• Ellis P. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust. NZ J. Psychiatry38(6), 389–407 (2004).
   PubMed Web of Science ®Google Scholar
• Hollander E, Bienstock CA, Koran LM et al. Refractory obsessive–compulsive disorder: state-of-the-art treatment. J. Clin. Psychiatry63(Suppl. 6), 20–29 (2002).
   PubMed Web of Science ®Google Scholar
• Durham RC. Treatment of generalized anxiety disorder. Psychiatry (2007) (In Press).
   Google Scholar
• Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive–compulsive disorder refractory to serotonin reuptake inhibitors. J. Clin. Psychiatry65(8), 1040–1048 (2004).
   PubMed Web of Science ®Google Scholar
• Lange JT, Lange CL, Cabaltica RB. Primary care treatment of post-traumatic stress disorder. Am. Fam. Physician62(5), 1035–1040 (2000).
   PubMed Web of Science ®Google Scholar
• Baker DG, Ekhator NN, Kasckow JW et al. Higher levels of basal serial CSF cortisol in combat veterans with posttraumatic stress disorder. Am. J. Psychiatry162(5), 992–994 (2005).
   PubMed Web of Science ®Google Scholar
• Otte C, Lenoci M, Metzler T et al. Hypothalamic–pituitary–adrenal axis activity and sleep in posttraumatic stress disorder. Neuropsychopharmacology30(6), 1173–1180 (2005).
   PubMed Web of Science ®Google Scholar
• Sapolsky RM, Alberts SC, Altmann J. Hypercortisolism associated with social subordinance or social isolation among wild baboons. Arch. Gen. Psychiatry54(12), 1137–1143 (1997).
   PubMed Web of Science ®Google Scholar
• Roman GC. Vascular depression: an archetypal neuropsychiatric disorder. Biol. Psychiatry60(12), 1306–1308 (2006).
   PubMedGoogle Scholar
• Dieguez S, Staub F, Bruggimann L, Bogousslavsky J. Is poststroke depression a vascular depression? J. Neurol. Sci.226(1–2), 53–58 (2004).
   PubMedGoogle Scholar
• Provinciali L, Coccia M. Post-stroke and vascular depression: a critical review. Neurol. Sci.22(6), 417–428 (2002).
   PubMed Web of Science ®Google Scholar
• Vataja R, Pohjasvaara T, Mantyla R et al. Depression-executive dysfunction syndrome in stroke patients. Am. J. Geriatr. Psychiatry13(2), 99–107 (2005).
   PubMed Web of Science ®Google Scholar
• Vataja R, Leppavuori A, Pohjasvaara T et al. Poststroke depression and lesion location revisited. J. Neuropsychiatry Clin. Neurosci.16(2), 156–162 (2004).
   PubMed Web of Science ®Google Scholar
• Sekine YM, Iyo MM, Tanaka KM et al. Effective adjunctive use of low-dose methylphenidate with mianserin for major depression with silent cerebral infarction: a case report. J. Clin. Psychopharmacol.20(5), 584–585 (2000).
   PubMedGoogle Scholar
• Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive–compulsive disorder. Clin. Psychol. Rev.24(8), 1011–1030 (2004).
   PubMed Web of Science ®Google Scholar
• Fricke S, Moritz S, Andresen B et al. Do personality disorders predict negative treatment outcome in obsessive–compulsive disorders? A prospective 6-month follow-up study. Eur. Psychiatry21(5), 319–324 (2006).
   PubMed Web of Science ®Google Scholar
• McKay D, Neziroglu F, Todaro J, Yaryura-Tobias JA. Changes in personality disorders following behavior therapy for obsessive–compulsive disorder. J. Anxiety Disord.10(1), 47–57 (1996).
   Google Scholar
• Miodownik C, Lerner V. Quetiapine: efficacy, tolerability and safety in schizophrenia. Expert Rev. Neurotherapeutics6(7), 983–992 (2006).
   PubMedGoogle Scholar
• Goldstein JM. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today35(3), 193–210 (1999).
   PubMed Web of Science ®Google Scholar
• Larmo I, de Nayer A, Windhager E et al. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Hum. Psychopharmacol.20(8), 573–581 (2005).
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J. Clin. Psychiatry63(Suppl. 13), 12–20 (2002).
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch. Gen. Psychiatry54(6), 549–557 (1997).
   PubMed Web of Science ®Google Scholar
• Pira L, Mongeau R, Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur. J. Pharmacol.504(1–2), 61–64 (2004).
   PubMed Web of Science ®Google Scholar
• Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res.956(2), 349–357 (2002).
   PubMed Web of Science ®Google Scholar
• Werkman TR, Olijslagers JE, Perlstein B et al. Quetiapine increases the firing rate of rat substantia nigra and ventral tegmental area dopamine neurons in vitro. Eur. J. Pharmacol.506(1), 47–53 (2004).
   PubMedGoogle Scholar
• Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive–compulsive disorder: a meta-analysis of the randomized controlled trials. Eur. Neuropsychopharmacol.17(2), 79–93 (2007).
   PubMed Web of Science ®Google Scholar
• Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res.1063(1), 32–39 (2005).
   PubMed Web of Science ®Google Scholar
• Park SW, Lee SK, Kim JM et al. Quetiapine regulates the stress-induced increase in corticotropin-releasing factor mRNA expression in the rat hypothalamus. Prog. Neuropsychopharmacol. Biol. Psychiatry31(2), 357–360 (2007).
   PubMedGoogle Scholar
• Cohrs S, Pohlmann K, Guan Z et al. Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects. Psychopharmacology174(3), 414–420 (2004).
   PubMed Web of Science ®Google Scholar
• Cohrs S, Roher C, Jordan W et al. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology185(1), 11–18 (2006).
   PubMed Web of Science ®Google Scholar
• Perrella C, Carrus D, Costa E, Schifano F. Quetiapine for the treatment of borderline personality disorder: an open-label study. Prog. Neuropsychopharmacol. Biol. Psychiatry31(1), 158–163 (2006).
   PubMedGoogle Scholar
• Mazaira S. Pharmacological treatment of borderline personality disorder. Vertex: Revista Argentina de Psiquiatria15(58), 303–308 (2004).
   Google Scholar
• Schmahl C, Bohus M. Symptom-focussed drug therapy in borderline personality disorder. Fortschr. Neurol. Psychiatr.69(7), 310–321 (2001).
   PubMed Web of Science ®Google Scholar
• Coccaro EFM, Kavoussi RJM. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch. Gen. Psychiatry54(12), 1081–1088 (1997).
   PubMed Web of Science ®Google Scholar
• Coccaro EF, Kavoussi RJ, Hauger RL. Serotonin function and antiaggressive response to fluoxetine: a pilot study. Biol. Psychiatry42(7), 546–552 (1997).
   PubMedGoogle Scholar
• Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J. Clin. Psychiatry67(7), 1042–1046 (2006).
   PubMed Web of Science ®Google Scholar
• Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J. Clin. Psychiatry66(10), 1298–1303 (2005).
   PubMed Web of Science ®Google Scholar
• Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline personality disorder. World J. Biol. Psychiatry4(1), 42–44 (2003).
   PubMed Web of Science ®Google Scholar
• Gruettert T, Friege L. Quetiapine in patients with borderline personality disorder and psychosis: a case series. International Journal of Psychiatry in Clinical Practice9(3), 180–186 (2005).
   PubMed Web of Science ®Google Scholar
• Ortigosa JC, Sotomayor E, Majadas S et al. The Trebol study. Quetiapine in the bordeline personality disorder: patient’s attitude and compliance. Eur. Psychiatry22(Suppl. 1), S175 (2007).
   Google Scholar
• Roepke S, Merkl A, Dams A et al. Quetiapine improves depressive and anxiety symptom but not impulsivity in cluster b personality disorder: an open label prospective trial. Eur. Psychiatry22(Suppl. 1), S176 (2007).
   Google Scholar
• Katzman MA, Struzik L, Vivian LL, Vermani M, McBride JC. Pharmacotherapy of post-traumatic stress disorder: a family practitioners guide to management of the disease. Expert Rev. Neurotherapeutics5(1), 129–139 (2005).
   PubMedGoogle Scholar
• Hamner MB, Robert S. Emerging roles for atypical antipsychotics in chronic post-traumatic stress disorder. Expert Rev. Neurotherapeutics5(2), 267–275 (2005).
   PubMedGoogle Scholar
• Pelak VS, Liu GT. Visual hallucinations. Curr. Treat. Options Neurol.6(1), 75–83 (2004).
   PubMedGoogle Scholar
• Hardy A, Fowler D, Freeman D et al. Trauma and hallucinatory experience in psychosis. J. Nerv. Ment. Dis.193(8), 501–507 (2005).
   PubMed Web of Science ®Google Scholar
• Hamner MB, Frueh BC, Ulmer HG et al. Psychotic features in chronic posttraumatic stress disorder and schizophrenia: comparative severity. J. Nerv. Ment. Dis.188(4), 217–221 (2000).
   PubMed Web of Science ®Google Scholar
• Ivezic S, Oruc L, Bell P. Psychotic symptoms in post-traumatic stress disorder. Mil. Med.164(1), 73–75 (1999).
   PubMedGoogle Scholar
• Sattar SP, Ucci B, Grant K, Bhatia SC, Petty F. Quetiapine therapy for posttraumatic stress disorder. Ann. Pharmacother.36(12), 1875–1878 (2002).
   PubMed Web of Science ®Google Scholar
• Ahearn EP, Mussey M, Johnson C, Krohn A, Krahn D. Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. Int. Clin. Psychopharmacol.21(1), 29–33 (2006).
   PubMed Web of Science ®Google Scholar
• Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J. Clin. Psychopharmacol.23(1), 15–20 (2003).
   PubMed Web of Science ®Google Scholar
• Kozaric-Kovacic D, Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int. J. Neuropsychopharmacol.10(2), 253–261 (2006).
   PubMedGoogle Scholar
• Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive–compulsive disorder. Psychiatr. Serv.54(8), 1111–1118 (2003).
   PubMed Web of Science ®Google Scholar
• Greist JH, Bandelow B, Hollander E et al. WCA recommendations for the long-term treatment of obsessive–compulsive disorder in adults. CNS Spectrums8(8 Suppl. 1), 7–16 (2003).
   PubMed Web of Science ®Google Scholar
• Greist JH, Jefferson JW. Pharmacotherapy for obsessive–compulsive disorder. Br. J. Psychiatry35, 64–70 (1998).
   Google Scholar
• Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive–compulsive disorder. J. Clin. Psychiatry60(2), 101–106 (1999).
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive–compulsive disorder: a randomized controlled treatment study. Int. Clin. Psychopharmacol.20(4), 223–226 (2005).
   PubMed Web of Science ®Google Scholar
• Carey PD, Vythilingum B, Seedat S et al. Quetiapine augmentation of SRIs in treatment refractory obsessive–compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry5(1), 5 (2005).
   PubMed Web of Science ®Google Scholar
• Denys D. Pharmacotherapy of obsessive–compulsive disorder and obsessive–compulsive spectrum disorders. Psychiatr. Clin. North Am.29(2), 553–584 (2006).
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive–compulsive disorder: a single-blind, placebo-controlled study. Int. Clin. Psychopharmacol.17(3), 115–119 (2002).
   PubMed Web of Science ®Google Scholar
• Mohr N, Vythilingum B, Emsley RA, Stein DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive–compulsive disorder. Int. Clin. Psychopharmacol.17(1), 37–40 (2002).
   PubMed Web of Science ®Google Scholar
• Misri SM, Milis LB. Obsessive–compulsive disorder in the postpartum: open-label trial of quetiapine augmentation. J. Clin. Psychopharmacol.24(6), 624–627 (2004).
   PubMed Web of Science ®Google Scholar
• Dell’Osso B, Mundo E, Altamura AC. Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a six-month follow-up case series. CNS Spectrums11(11), 879–883 (2006).
   PubMed Web of Science ®Google Scholar
• Denys D, Fineberg N, Carey PD, Stein DJ. Quetiapine addition in obsessive–compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol. Psychiatry61(3), 412–414 (2007).
   PubMed Web of Science ®Google Scholar
• Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A. Quetiapine augmentation in obsessive–compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J. Clin. Psychiatry66(1), 73–79 (2005).
   PubMed Web of Science ®Google Scholar
• Sevincok L, Topuz A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive–compulsive disorder. J. Clin. Psychopharmacol.23(5), 448–450 (2003).
   PubMed Web of Science ®Google Scholar
• Mitchell PB, Malhi GS, Redwood BL, Ball J. Summary of guideline for the treatment of bipolar disorder. Australas. Psychiatry11(1), 39–53 (2003).
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry159(Suppl.) 4, 1–50 (2002).
   Web of Science ®Google Scholar
• Stratta P, de Cataldo S, Mancini G et al. Quetiapine as adjunctive treatment of a case of rapid-cycling bipolar disorder with comorbidity. Hum. Psychopharmacol.18(7), 559–560 (2003).
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Brescan DW, Perez DE et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J. Clin. Psychiatry62(9), 728–732 (2001).
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J. Clin. Psychiatry61(3), 185–189 (2000).
   PubMed Web of Science ®Google Scholar
• Sachs G, Chengappa KNR, Suppes T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord.6(3), 213–223 (2004).
   PubMed Web of Science ®Google Scholar
• Yoon BH, Bahk WM, Jon DI et al. The effect of quetiapine monotherapy on subjective estimates of sleep in acute mania. Eur. Psychiatry22(Suppl. 1), S263 (2007).
   Google Scholar
• Kaya DF, Sayin A, Biri A. Quetiapine use in manic episode during pregnancy: a case report. Eur. Psychiatry22(Suppl. 1), S166–S167 (2007).
   Google Scholar
• Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. J. Psychiatr. Neurosci.29(6), 452–457 (2004).
   PubMed Web of Science ®Google Scholar
• Pettinati HM, Kampman KM, Macfadden W et al. Randomized, placebo-controlled trial of quetiapine for the treatment of alcohol dependence: 407. Alcohol. Clin. Exp. Res.30(6), 108A (2006).
   Google Scholar
• Monnelly EP, Ciraulo DA, Knapp C, LoCastro J, Sepulveda I. Quetiapine for treatment of alcohol dependence. J. Clin. Psychopharmacol.24(5), 532–535 (2004).
   PubMed Web of Science ®Google Scholar
• Brown ES, Nejtek VA, Perantie DC, Bobadilla L. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord.4(6), 406–411 (2002).
   PubMed Web of Science ®Google Scholar
• Croissant B, Klein O, Gehrlein L et al. Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series. Eur. Psychiatry21(8), 570–573 (2006).
   PubMed Web of Science ®Google Scholar
• Jarema M. Atypical antipsychotics in the treatment of mood disorders. Curr. Opin. Psychiatry20(1), 23–29 (2007).
   PubMedGoogle Scholar
• Konstantinidis A, Hrubos W, Nirnberger G et al. Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Prog. Neuropsychopharmacol. Biol. Psychiatry31(1), 242–247 (2007).
   PubMed Web of Science ®Google Scholar
• Doree JP, Des RJ, Lew V et al. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr. Med. Res. Opin.23(2), 333–341 (2007).
   PubMed Web of Science ®Google Scholar
• Sagud M, Mihaljevi-Peles A, Muck-Seler D, Jakovljevi M, Pivac N. Quetiapine augmentation in treatment-resistant depression: a naturalistic study. Psychopharmacology187(4), 511–514 (2006).
   PubMed Web of Science ®Google Scholar
• Pathak S, Johns ES, Kowatch RA. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. J. Child Adolesc. Psychopharmacol.15(4), 696–702 (2005).
   PubMed Web of Science ®Google Scholar
• Moeller O, Hetzel G, Arolt V. Quetiapine in the treatment of agitation in major depressive disorder. Eur. Neuropsychopharmacol.14(Suppl. 3), S176 (2004).
   Google Scholar
• Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress. Anxiety20(1), 44–47 (2004).
   PubMed Web of Science ®Google Scholar
• Hussain MZ, Waheed W, Hussain S. A comparison of unipolar depression treatment using antidepressants alone versus using antidepressants in combination with quetiapine (4-year follow-up). Eur. Neuropsychopharmacol.16(Suppl. 4), S325 (2006).
   Google Scholar
• He J, Xu H, Yang Y, Zhang X, Li XM. Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats. Behav. Brain Res.160(1), 178–187 (2005).
   PubMed Web of Science ®Google Scholar
• Schutters SI, Van Megen HG, Westenberg HG. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. Eur. Neuropsychopharmacol.15(Suppl. 3), S535 (2005).
   Google Scholar
• Targum SD, Hassman H, Bastani M, Bari M, Ramirez L. Quetiapine reduces persistent anxiety in patients with major depressive disorder. Eur. Neuropsychopharmacol.14(Suppl. 3), S298–S299 (2004).
   Google Scholar
• Moeller HJ, Johnson S, Mateva T et al. Continued efficacy and tolerability in clinically stable patients switched from quetiapine immediate release (IR) to quetiapine sustained release (SR). Eur. Psychiatry22(Suppl. 1), S126–S127 (2007).
   Google Scholar
• Khullar A, Chue P, Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J. Psychiatr. Neurosci.26(1), 55–59 (2001).
   PubMedGoogle Scholar
• Feret BM, Caley CF. Possible hypothyroidism associated with quetiapine. Ann. Pharmacother.34(4), 483–486 (2000).
   PubMedGoogle Scholar
• Liappas J, Paparrigopoulos T, Mourikis I, Soldatos C. Hypothyroidism induced by quetiapine: a case report. J. Clin. Psychopharmacol.26(2), 208–209 (2006).
   PubMedGoogle Scholar
• Andres Prado MJ, Vidal FM. Priapism associated with quetiapine in an elderly patient. Actas Esp. Psiquiatr.34(3), 209–210 (2006).
   PubMed Web of Science ®Google Scholar
• Harrison G, Dilley JW, Loeb L, Nelson K. Priapism and quetiapine in an HIV-positive male. J. Clin. Psychopharmacol.26(1), 100–101 (2006).
   PubMedGoogle Scholar
• Davol P, Rukstalis D. Priapism associated with routine use of quetiapine: case report and review of the literature. Urology66(4), 880 (2005).
   PubMed Web of Science ®Google Scholar
• Clark N, Weissberg E, Noel J. Quetiapine and leukopenia. Am. J. Psychiatry158(5), 817–818 (2001).
   PubMed Web of Science ®Google Scholar
• Matsumoto R, Kitabayashi Y, Nakatomi Y, Tsuchida H, Fukui K. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. Am. J. Psychiatry162(4), 812 (2005).
   PubMed Web of Science ®Google Scholar
• Huynh M, Chee K, Lau DH. Thrombotic thrombocytopenic purpura associated with quetiapine. Ann. Pharmacother.39(7), 1346–1348 (2005).
   PubMed Web of Science ®Google Scholar
• Valibhai F, Phan NB, Still DJ, True J. Cataracts and quetiapine. Am. J. Psychiatry158(6), 966 (2001).
   PubMedGoogle Scholar
• Fraunfelder FW. Twice-yearly exams unnecessary for patients taking quetiapine. Am. J. Ophthalmol.138(5), 870–871 (2004).
   PubMed Web of Science ®Google Scholar
• Gaynes BI. Twice-yearly exams unnecessary for patients taking quetiapine. Am. J. Ophthalmol.140(2), 348–349 (2005).
   PubMedGoogle Scholar
• Woodcock J. Pharmacogenetics: on the road to ‘personalized medicine’. FDA Consumer39(6), 44 (2005).
   PubMedGoogle Scholar
• Sunderland T, Hampel H, Takeda M, Putnam KT, Cohen RM. Biomarkers in the diagnosis of alzheimer’s disease: are we ready? J. Geriatr. Psychiatry Neurol.19(3), 172–179 (2006).
   PubMed Web of Science ®Google Scholar
• Charney DS, Barlow DH, Botteron K et al. Neuroscience research agenda to guide development of a pathophysiologically based classification system. In: A Research Agenda for DSM-V. Kupfer DJ, First MB, Regier DA (Eds). American Psychiatric Association, Washington, DC, USA 31–84 (2002).
   Google Scholar
• Nigg JT, Willcutt EG, Doyle AE, Sonuga-Barke EJS. Causal heterogeneity in attention-deficit/hyperactivity disorder: do we need neuropsychologically impaired subtypes? Biol. Psychiatry57(11), 1224–1230 (2005).
   PubMed Web of Science ®Google Scholar
• Rich BA, Schmajuk M, Perez-Edgar KE et al. Different psychophysiological and behavioral responses elicited by frustration in pediatric bipolar disorder and severe mood dysregulation. Am. J. Psychiatry164(2), 309–317 (2007).
   PubMed Web of Science ®Google Scholar
• Peled A. Brain profiling and clinical-neuroscience. Med. Hypotheses67(4), 941–946 (2006).
   PubMedGoogle Scholar
• Kupfer DJ. DSM-V: plans and perspectives. Presented at: American Psychiatric Association 155th Annual Meeting. PA, USA, 18–23 May 2002.
   Google Scholar
• Gordon E. Integrative neuroscience: the big picture. In: Integrative Neuroscience: Bringing Together Biological, Psychological and Clinical Models of the Human Brain. Gordon E (Ed.). Harwood Academic Publishers, Amsterdam, The Netherlands 1–28 (2000).
   Google Scholar
• Gordon E. Integrative neuroscience. Neuropsychopharmacology.28(Suppl.), S2–S8 (2003).
   PubMedGoogle Scholar
• Gordon E, Cooper N, Rennie C, Hermens D, Williams LM. Integrative neuroscience: the role of a standardised database. Australas. Psychiatry11(2), 156–163 (2003).
   Google Scholar
• Gordon E, Cooper N, Rennie C, Hermens D, Williams LM. Integrative neuroscience: the role of a standardized database. Clin. EEG Neurosci.36(2), 64–75 (2005).
   PubMed Web of Science ®Google Scholar
• Hermens DF, Rowe DL, Gordon E, Williams LM. Integrative neuroscience approach to predict ADHD stimulant response. Expert Rev. Neurotherapeutics6(5), 753–763 (2006).
   PubMed Web of Science ®Google Scholar
• Rowe DL, Hermens DF. Attention-deficit/hyperactivity disorder: neurophysiology, information processing, arousal and drug development. Expert Rev. Neurotherapeutics6(11), 1721–1734 (2006).
   PubMedGoogle Scholar
• Rowe DL, Cooper NJ, Liddell BJ, Clark CR, Williams LM. Brain structure and brain function correlates of general and social cognition. J. Integr. Neurosci.6(1), 35–74 (2007).
   PubMedGoogle Scholar
• Johnstone J, Gunkelman J, Lunt J. Clinical database development: characterization of EEG phenotypes. Clin. EEG Neurosci.36(2), 99–107 (2005).
   PubMed Web of Science ®Google Scholar